Research & Development

With its liposomal technology platform, InnoMedica offers almost unlimited possibilities for improving existing drugs. Our researchers are restricted from reaching these goals primarily by financial limits—which imposes a strict prioritization in the pipeline. The team around Dr. Camille Peitsch is currently focused on developing Talineuren in the lab and the translation of this product into the clinic. The team is tireless identifying and prioritizing future projects for our pipeline from the fields of neurology, oncology, infectiology and immunology.

Dr. Camille Peitsch – PhD in Biochemistry and Molecular Biology, University of Bern
Dr. Silvia Erni – PhD in Biomedical Sciences, University of Bern
Dr. Pascal Häfliger – PhD in Biomedical Sciences, University of Bern; previously: Postdoc at the Herbert Irving Comprehensive Cancer Center, Columbia University New York
Dr. Marion Kieffer – PhD in Chemistry, University of Cambridge (UK); previously: Research Associate, University of Bristol (UK)
Dr. Melanie Patt – PhD in Pharmaceutical Sciences, University of Basel
Dr. Diego von Werdt – PhD in Immunology, University of Bern